MannKind Corporation (MNKD:NASDAQ) closed at $3.04 on October 16, 2026, down 4.70% on the day. The stock trades 53.3% below its 52-week high of $6.51 and 36.3% above its 52-week low of $2.23. Over the past year, it lost 44.4%. MannKind Corporation is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -2.88% | -15.08% | -23.62% | +4.11% | -44.42% |
In 252 trading sessions since October 16, 2025, MNKD closed higher on 112 days (44%). Its best day was May 6, 2026 (+24.48%) and its worst was February 25, 2026 (-36.82%). The stock moved 10% or more in a single session 5 times. It opened at least 5% above the previous day's high 2 times.
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The company was founded in 1991 and is based in Valencia, California.
Find more stocks like MNKD with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.